PFSA
Profusa, Inc. Common Stock
NASDAQ · Healthcare · Medical - Equipment & Services · US
$2.72
+3.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.0K | — | — | — | — |
| Gross Profit | (2.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.9M | 2.8M | 1.6M | 2.0M | 4.2M |
| SG&A Expense | 27.9M | 24.9M | 3.0M | 4.1M | 5.2M |
| General & Admin Expense | 2.3M | 24.9M | 3.0M | 4.1M | 5.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (14.5M) | (100.0K) | (45.0K) | 1.7M |
| Total Operating Expenses | 31.8M | 13.2M | 4.5M | 6.1M | 11.1M |
| Cost and Expenses | 31.8M | 13.2M | 4.5M | 6.1M | 11.1M |
| Operating Income (EBIT) | (31.8M) | (13.2M) | (4.5M) | (6.1M) | (11.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 5.3M | 5.1M | 4.4M | 4.3M | 6.3M |
| Net Interest Income | (5.3M) | (5.1M) | (4.4M) | (4.3M) | (6.3M) |
| Other Non-Op Income/Expense | (11.1M) | (22.6M) | (4.7M) | (4.2M) | (9.1M) |
| Non-Operating Income (excl Interest) | 3.2M | 17.5M | 306.0K | (72.0K) | 2.8M |
| EBT (Pre-Tax Income) | (43.0M) | (35.8M) | (9.2M) | (10.3M) | (20.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (43.0M) | (35.8M) | (9.2M) | (10.3M) | (20.2M) |
| Earnings from Cont. Ops | (43.0M) | (35.8M) | (9.2M) | (10.3M) | (20.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (43.0M) | (35.8M) | (9.2M) | (10.3M) | (20.2M) |
| Per Share | |||||
| Basic EPS | ($213.25) | ($107.01) | ($357.13) | ($76.65) | ($62.74) |
| Diluted EPS | ($213.25) | ($107.01) | ($357.13) | ($76.65) | ($62.74) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 57676 | 334770 | 25844 | 134134 | 322249 |
| Diluted Shares Outstanding | 57676 | 334770 | 25844 | 134134 | 322249 |
| Profitability Metrics | |||||
| EBITDA | (35.0M) | (30.7M) | (4.8M) | (6.0M) | (13.2M) |
| D&A | 2.0K | — | — | — | 724.0K |
| EBIT | (35.0M) | (30.7M) | (4.8M) | (6.0M) | (13.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026